Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Director departure
Anthera Pharmaceuticals Inc (ANTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/09/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Anthera Pharmaceuticals Announces SEC Deregistration"
06/27/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets"
06/18/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement between Anthera Pharmaceuticals, Inc. and Craig Thompson"
05/30/2018 8-K Other Events
05/23/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/16/2018 8-K Quarterly results
03/12/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura"
03/05/2018 8-K Quarterly results
01/25/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Anthera Receives Positive Nasdaq Listing Determination"
01/09/2018 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering"
11/17/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Anthera Pharmaceuticals Announces Expected Receipt of Nasdaq Listing Determination Notice and Plans Appeal"
11/06/2017 8-K Quarterly results
Docs: "Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results"
10/25/2017 8-K Quarterly results
08/28/2017 8-K Quarterly results
08/09/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy"
08/09/2017 8-K Quarterly results
Docs: "Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results"
07/14/2017 8-K Form 8-K - Current report:
06/19/2017 8-K Form 8-K - Current report
05/25/2017 8-K Form 8-K - Current report
05/18/2017 8-K Form 8-K - Current report
05/10/2017 8-K Form 8-K - Current report
04/28/2017 8-K Form 8-K - Current report
04/27/2017 8-K Form 8-K - Current report
03/30/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
02/16/2017 8-K Form 8-K - Current report
01/06/2017 8-K Form 8-K - Current report
12/27/2016 8-K Form 8-K - Current report
12/06/2016 8-K Form 8-K - Current report
12/01/2016 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
11/04/2016 8-K Quarterly results
Docs: "Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results"
09/15/2016 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy